Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer

Coskun,Teoman; Kosova,Funda; Ari,Zeki; Sakarya,Aslan; Kaya,Yavuz

doi:10.3892/mco.2016.815

Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer

Authors:
- Teoman Coskun
- Funda Kosova
- Zeki Ari
- Aslan Sakarya
- Yavuz Kaya
View Affiliations

Affiliations: Department of General Surgery, Faculty of Medicine, Celal Bayar University, 45030 Manisa, Turkey, School of Health, Celal Bayar University, 45030 Manisa, Turkey, Department of Biochemistry, Faculty of Medicine, Celal Bayar University, 45030 Manisa, Turkey
Published online on: March 10, 2016 https://doi.org/10.3892/mco.2016.815
Pages: 893-897

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipose tissue-derived hormones (adipocytokines), such as adiponectin, leptin, resistin and visfatin, and the pancreatic hormone insulin, have been suggested to play a role in carcinogenesis. we therefore hypothesized that the oncological treatment of breast cancer may alter the serum levels of these adipocytokines and insulin. In this study, we aimed to compare the serum levels of adipocytokines and insulin between the pre‑ and post-treatment period in patients with breast cancer. In this prospective study, 20 consecutive patients with stage II and III breast cancer underwent breast‑conserving surgery or total mastectomy and/or axillary dissection. The patients received adjuvant chemotherapy and radiotherapy, if necessary. Blood samples were obtained during the preoperative period and postoperatively after completion of the adjuvant therapy. There was no statistically significant difference between the pre- and post-treatment levels of visfatin, adiponectin and leptin. However, the serum insulin and resistin levels and insulin resistance were found to be statistically significantly increased following treatment (P<0.05). Post-treatment resistin levels were positively correlated with insulin resistance (r=0.45, P<0.05). Therefore, oncological treatment of stage II and III breast cancer did not affect visfatin, adiponectin and leptin levels, but statistically significantly increased resistin levels and insulin resistance. In addition, the post‑treatment resistin levels were positively correlated with insulin resistance, suggesting that resistin may be involved in the development of insulin resistance in breast cancer patients following treatment.

View Figures

View References

1	Stoll BA: Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord. 26:747–753. 2002.PubMed/NCBI
2	Macciò A, Madeddu C and Mantovani G: Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: New therapeutic perspectives. Obes Rev. 10:660–670. 2009. View Article : Google Scholar : PubMed/NCBI
3	Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF and Yuan SS: Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 237:109–114. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC and Sun CA: Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 100:578–582. 2009. View Article : Google Scholar : PubMed/NCBI
5	Dalamaga M, Archondakis S, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E and Lekka A: Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas. 71:301–308. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kang JH, Yu BY and Youn DS: Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 22:117–121. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E and Lekka A: Serum resistin: A biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 46:584–590. 2013. View Article : Google Scholar : PubMed/NCBI
8	Jardé T, Perrier S, Vasson MP and Caldefie-Chézet F: Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 47:33–43. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C and Mussa A: Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 5:421–426. 2000.PubMed/NCBI
10	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). Springer. New York, NY: 2010.
11	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
12	Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, Namgoong IS, Kim YI and Lee BJ: Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells. 30:341–345. 2010. View Article : Google Scholar : PubMed/NCBI
13	Filková M, Haluzík M, Gay S and Senolt L: The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 133:157–170. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ and Xu A: Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 66:11462–11470. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kosova F, Coskun T, Kaya Y, Kara E and Ari Z: Adipocytokine levels of colon cancer patients before and after treatment. Bratisl Lek Listy. 114:394–397. 2013.PubMed/NCBI
16	Thompson LH and Suit HD: Proliferation kinetics of x-irradiated mouse L cells studied WITH TIME-lapse photography. II. Int J Radiat Biol Relat Stud Phys Chem Med. 15:347–362. 1969. View Article : Google Scholar : PubMed/NCBI
17	Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res. 159:283–300. 2003. View Article : Google Scholar : PubMed/NCBI
18	Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P and Okunieff P: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 12(Suppl 1): 26–33. 2002. View Article : Google Scholar : PubMed/NCBI
19	Rubin P, Johnston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:99–109. 1995. View Article : Google Scholar : PubMed/NCBI
20	Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB and Anscher MS: Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor β. Int J Radiat Oncol Biol Phys. 50:899–908. 2001. View Article : Google Scholar : PubMed/NCBI
21	Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C and Kolesnick R: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 293:293–297. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hauer-Jensen M, Kong FM, Fink LM and Anscher MS: Circulating thrombomodulin during radiation therapy of lung cancer. Radiat Oncol Investig. 7:238–242. 1999. View Article : Google Scholar : PubMed/NCBI
23	Kaaks R: Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control. 7:605–625. 1996. View Article : Google Scholar : PubMed/NCBI
24	Vona-Davis L, Howard-McNatt M and Rose DP: Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 8:395–408. 2007. View Article : Google Scholar : PubMed/NCBI
25	Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML and Draznin B: Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 276:38023–38028. 2001.PubMed/NCBI
26	Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D and De Meyts P: Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia. 40(Suppl 2): S25–S31. 1997. View Article : Google Scholar : PubMed/NCBI
27	Shafie SM and Hilf R: Insulin receptor levels and magnitude of insulin-induced responses in 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Cancer Res. 41:826–829. 1981.PubMed/NCBI
28	Shafie SM and Grantham FH: Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst. 67:51–56. 1981.PubMed/NCBI
29	Mink PJ, Shahar E, Rosamond WD, Alberg AJ and Folsom AR: Serum insulin and glucose levels and breast cancer incidence: The atherosclerosis risk in communities study. Am J Epidemiol. 56:349–352. 2002. View Article : Google Scholar
30	Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN and Hankinson SE: Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev. 16:161–164. 2007. View Article : Google Scholar : PubMed/NCBI
31	Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 101:48–60. 2009. View Article : Google Scholar : PubMed/NCBI
32	Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ, et al: Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 125:2704–2710. 2009. View Article : Google Scholar : PubMed/NCBI
33	Guinan E, Connolly EM, Healy LA, Carroll PA, Kennedy MJ and Hussey J: The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer. Cancer Nurs. 37:355–362. 2014.PubMed/NCBI
34	American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 35(Suppl 1): S62–S69. 2010.
35	Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K and Rimer BK: Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 19:2381–2389. 2001.PubMed/NCBI
36	Carr MC: The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 88:2404–2411. 2003. View Article : Google Scholar : PubMed/NCBI
37	Kaaja RJ: Metabolic syndrome and the menopause. Menopause Int. 14:21–25. 2008.PubMed/NCBI
38	Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS and Lazar MA: The hormone resistin links obesity to diabetes. Nature. 409:307–312. 2001. View Article : Google Scholar : PubMed/NCBI